Greater China startups raise $17b in Q2, but scrutiny of tech firms mars future prospects
July 29, 2021
Greater China startups saw decent fund flows from private equity (PE) and venture capital (VC) investors, and also a buoyant IPO market, in April-June 2021. Yet, investors are bracing for a tough period ahead amid Beijing’s tightening regulatory scrutiny of the country’s tech giants.
In Q2 2021, nearly $17 billion worth of deals were sealed between startups and PE-VCs, showed data from our latest DATA
VANTAGE report Greater China Deal Review: Q2 2021. While this is down 29.7% sequentially, mainly due to the absence of billion-dollar investments, dealmaking was still more vibrant than in COVID-marred Q2 2020 when startups collected only around $9.5 billion
March rebound shores up Greater China PE-VC dealmaking in Q1, as startups raise $24b
Photo: Li Yang/ Unsplash.com
April 22, 2021
Lukewarm dealmaking in Greater China in January and February this year mostly attributable to the week-long New Year holiday was more than offset by a sharp rebound in March.
Private Equity (PE) and Venture Capital (VC) investors poured a record $11.4 billion into 199 startups in the last month of the quarter, after two months of relative lull, according to DealStreetAsia’s Greater China Deal Review: Q1 2021 report.
This shored up PE-VC funding activity in Q1 2021 to at least $24.1 billion across 464 deals the best performance in the past six quarters, and an uptick of 1.2% in terms of deal value and 5.9% in terms of deal count, compared with the previous quarter (Q4 2020).
Sequoia China partners with Chinese insurer to launch health industry fund
Sequoia National Park, United States. Source:
Vladimir Kudinov/Unsplash
January 29, 2021
Sequoia Capital China, widely viewed as a bellwether for Chinese tech investment, has joined hands with insurer China Pacific Insurance to create an industry-specific fund to invest in health-related new technologies and business models, Sequoia China announced on Thursday.
The fund will focus on investment opportunities in the overall health sector, covering biopharmaceutical, medical devices, medical services, digital health, and beyond.
The duo plans to leverage a market-driven investment platform and “patient capital” from the insurance firm to create a larger room for cooperation and synergies between health investments and the commercial insurance area. Sequoia China declined to disclose the size of the new fund.